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Background: Protein Kinases are key regulators of cell function and play essential roles in the occurrence and
development of many human diseases. Many kinase inhibitors have been used for molecular targeted treatment of
those diseases such as cancer and inflammation. However, those highly hydrophobic kinase inhibitors shared the
common features of poor bioavailability and limited in vivo half-life, which strongly impeded their practical applications.
Our previous study demonstrated that microbial synthesized biodegradable polyester poly(3-hydroxybutyrate-co-3-
hydroxyhexanoate) (PHBHHx), a member of polyhydroxyalkanoates (PHAs) family, could serve as a promising delivery
nanocarrier for those hydrophobic kinase inhibitors. Recently, a novel natural synthesized hybrid copolymer, PEG200
end-capped PHBHHx (PHBHHxPEG) was produced by Aeromonas hydrophila fermentation. In this study, the novel
PHBHHxPEG NPs were prepared and investigated to serve as intracellular delivery nanocarriers for sustained release of
hydrophobic kinase inhibitors.
Results: PHBHHxPEG nanoparticles (NPs) prepared by an emulsification–solvent evaporation method were spherical
with a diameter around 200 nm. The entrapment efficiency on rapamycin in PHBHHxPEG NPs was 91.9% and the
sustained release of rapamycin from PHBHHxPEG NPs could be achieved for almost 10 days. The cellular uptake of
PHBHHxPEG NPs was significant higher than that of PHBHHx NPs. The anti-proliferation effect and mTOR inhibition
ability of rapamycin-loaded PHBHHxPEG NPs was stronger than that of drug-loaded PHBHHx NPs and free rapamycin.
Conclusions: PHBHHxPEG NPs could achieve the efficient entrapment and sustained release of rapamycin. The novel
biodegradable PHBHHxPEG appeared a promising nanocarrier for sustained delivery of hydrophobic kinase inhibitors
with improved cellular uptake and kinase inhibition efficiency.
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Protein kinases play essential roles in signal transduction
and regulation by phosphorylating other proteins to alter
their enzymatic activity, cellular location, or association
with other proteins. Phosphorylation of the target pro-
tein is a necessary and key step in the occurrence and
development of some cancers and inflammatory diseases.
Therefore, protein kinase inhibitors which specifically
block the action of one or more protein kinases have* Correspondence: luxy05@mail.xjtu.edu.cn
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reproduction in any medium, provided the orbeen used as drugs for molecular targeted treatment
of cancer and inflammatory diseases. However, poor
bioavailability and limited in vivo half-life are rather
common features of many kinase inhibitors that usually
are highly hydrophobic compounds. For example, rapa-
mycin (RAP, also known as Sirolimus) isolated from
Streptomyces hygroscopicus is such kind of hydrophobic
kinase inhibitor which has already been approved by
US Food and Drug Administration (FDA) as an im-
munosuppressive drug to prevent the rejection of solid
organ transplants [1]. RAP is a natural inhibitor of the
mammalian target of rapamycin (mTOR) which is a
critical regulator of cell growth, proliferation and sur-
vival. Dysregulation of mTOR activities often occurs in
a variety of human malignant diseases, making it a crucialThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-proliferation activity of RAP was evaluated and it
was found that RAP could also inhibit the proliferation
of a number of tumor cell lines [3]. However, since it is
a strongly hydrophobic compound and only slightly sol-
uble in several acceptable excipients such as ethanol,
propylene glycol and polyethylene glycol 400 [4], RAP
is only available in oral but with a relative low bioavail-
ability of around 17% [5]. Therefore, conventional dosage
formulations of RAP could not fulfill the demand for
anti-proliferation therapy.
Biodegradable polymeric nanoparticles are more and
more frequently used in drug delivery systems and rep-
resent one of the most rapidly developing areas, which
have now attracted growing interest of chemists, phar-
macists and biologists. Nanosized polymeric nanoparti-
cles provide a comprehensive platform for achieving the
enhanced drug solubility/stability, improving the effect-
iveness of drug therapy and reducing the side effects of
the loaded drug to healthy tissues. Many different natural
and synthetic polymers have been developed as drug de-
livery carriers. Polyhydroxyalkanoates (PHAs) are a family
of biodegradable aliphatic polyesters which are synthe-
sized by a wide range of bacteria. PHAs have been exten-
sively studied as implantable tissue repair/regeneration
devices and other biomedical devices such as sutures and
suture fasteners, because of their good biocompatibility
and biodegradability [6,7]. Recently, PHAs have also been
explored for controlled drug-release applications [8,9].
Based on their polyester aliphatic properties, PHAs are
more efficient in encapsulating the hydrophobic com-
pounds and thus would be especially beneficial for hydro-
phobic drugs. Several commercialized PHAs, for example,
polyhydroxybutyrate (PHB) and poly(3-hydroxybutyrate-
co-3-hydroxy-hexanoate) (PHBHHx), have been success-
fully developed into nanoparticles and investigated for
the entrapment and release profiles of hydrophobic
compounds. The drug-loaded PHA nanoparticles dem-
onstrated sustained release of hydrophobic drugs and
enhanced bioavailability in cell-based assays [8].
In our previous studies, a novel naturally synthesized









Abbreviations: NPs nanoparticles, Dmean, mean diameter, SD standard deviation, PDIcapped poly(3-hydroxybutyrate-co-3- hydroxyhexanoate)
(PHBHHxPEG) was directly produced by Aeromonas
hydrophila fermentation [10]. In this study, the novel
PHBHHxPEG NPs were prepared and investigated to
serve as the nanocarrier for sustained release of a hydro-
phobic kinase inhibitor like RAP. RAP cellular uptake of
PHBHHxPEG NPs, in vitro release of RAP from the
NPs, cellular proliferation inhibition and kinase inhib-
ition of RAP-loaded NPs were investigated. The results
obtained in this study indicated that the microbial syn-
thesized PHBHHxPEG hybrid copolymer represents a
promising material to serve as an intracellular drug de-
livery carrier for sustained release of hydrophobic kinase
inhibitors.
Results
Preparation and characterization of PHBHHx and
PHBHHxPEG NPs
Two kinds of free nanoparticles (PHBHHx and PHBHHxPEG),
two kinds of rhodamine-loaded nanoparticles (PHBHHx
and PHBHHxPEG) and three kinds of rapamycin-loaded
nanoparticles (PLA, PHBHHx and PHBHHxPEG) were
prepared by an emulsification–solvent evaporation tech-
nique. The sizes and polydispersities of the nanoparti-
cles were listed in Table 1. Figure 1 showed the TEM
photographs and the size distribution of PHBHHx and
PHBHHxPEG NPs, respectively. The sizes of nanoparticles
ranged from 100 to 300 nm after 6 h stirring with relative
low polydispersity index (PDI). At the drug/material feed-
ing ratio of 1:10, entrapment efficiency (EE) of rapamycin
in both PHBHHx and PHBHHxPEG NPs were higher
than 90%. The drug loading content (DLC) of RAP-loaded
PHBHHx and PHBHHxPEG NPs were 8.52% and 8.47%,
respectively. PLA NPs demonstrated lower entrapment
ability compared with PHBHHx and PHBHHxPEG NPs,
which was consisted with our previous report.
In vitro release of rapamycin
Three kinds of RAP-loaded NPs were prepared based on
PLA, PHBHHx and PHBHHxPEG, respectively. Figure 2
shows the in vitro release profiles of RAP-loaded NPs
in water at 37°C. PLA and PHBHHxPEG NPs showedpamycin/rhodamine-loaded nanoparticles








polydispersity index, EE Entrapment efficiency.
Figure 1 TEM photographs (A, B) and the NPs size distribution (C, D) of PHBHHx NPs (A, C) and PHBHHx-PEG NPs (B, D).
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sustained discharge stage, which was a little bit faster
than that from PHBHHx NPs. About 40% of the drug
could be released within the first 24 hrs from PLA NPs
and PHBHHx-PEG NPs and only about 30% of RAP was
released from PHBHHx NPs during the same period. At
75 hours, the percentage of retained drug in PHBHHx andFigure 2 In vitro release profiles of RAP-loaded PHBHHx, PHBHHxPEGPHBHHxPEG NPs were 42% and 25%, respectively, which
demonstrated that the release of RAP from PHBHHxPEG
NPs was faster than that from PHBHHx NPs.
Interestingly, the release of RAP from PHA-based NPs
was more efficient than that from PLA NPs. Indeed,
more than 95% of the drug could be released from the
PHBHHx and PHBHHxPEG NPs after 10 days. On theand PLA nanoparticles.
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NPs even after 10 days, which indicated that this 30% of
drug was strongly encapsulated in the PLA NPs and
could not be released. Such behavior might be explained
by the relativly poor crystalline nature of PHBHHx and
PHBHHxPEG materials, thus allowing RAP to diffuse
from the loose particle core. These results thus indi-
cated that the PHBHHx and PHBHHxPEG nanoparti-
cles could efficiently and effectively extend the release
profile of RAP and could be eventually used as con-
trolled delivery carriers for hydrophobic drugs.
Cellular uptake of PHBHHx and PHBHHxPEG NPs
Human prostate cancer cell line PC3 and a murine macro-
phage cell line RAW264.7 were used to investigate the
in vitro endocytosis of PHA-based NPs. Cells were treated
with the rhodamine B solution, rhodamine B-loaded
PHBHHx NPs and PHBHHxPEG NPs in the sameFigure 3 Uptake of PHBHHx and PHBHHxPEG nanoparticles by PC3 a
B: Intracellular fluorescence intensities quantification by fluorescencefluorescence intensity, respectively. After 3 hrs treatment,
the intracellular fluorescence of the rhodamine B solution
treated group was weak in both PC3 and RAW264.7 cells,
which suggested that rhodamine B could not be easily
absorbed by both these two cell lines (Figure 3A). However,
significant intracellular fluorescence signal could be de-
tected either by the fluorescence microscopy observation
(Figure 3A) or by fluorescence intensity analysis (Figure 3B)
in both PC3 and RAW264.7 cells 3 hrs after the addition
of rhodamine B–loaded NPs. The internalized NPs were
mainly accumulated in the cytoplasm and didn’t reach the
cell nucleus area, indicated by the weak fluorescence inten-
sity area inside the cells. Moreover, the rhodamine B–
loaded PHBHHxPEG NPs treating group showed much
stronger intracellular fluorescence intensity compared to
the rhodamine B–loaded PHBHHx NPs treating group,
indicating that PHBHHxPEG NPs showed higher cell affin-
ity and easier cellular uptake.nd RAW264.7 cells. A: Fluorescence microscopy pictures;
spectrophotometer.
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PHBHHxPEG NPs
The cytotoxic effect of PHBHHx and PHBHHxPEG NPs
on PC3 was evaluated in vitro by MTT assay. Figure 4
shows relative proliferation percentage of PC3 incubated
with different NPs at doses of 100, 500 and 1000 μg ml-1
for 24 h, respectively. PHBHHx and PHBHHxPEG NPs
could be well tolerated at the concentration of 100 μg ml-1.
However, decreased cell viability was observed in the
groups treated with 1000 μg ml-1 and 500 μg ml-1 NPs,
which resulted in 40% and 20% decrease of cell viability,
respectively. PHBHHx NPs and PHBHHxPEG NPs-
treated groups did not show significant difference in
cell viability.
Effects of rapamycin-loaded NPs on proliferation of
PC3 cells
The anti-proliferation effect of RAP-loaded NPs on PC3
cells was evaluated by the MTT assay. Cells were treated
with 10 μM free RAP, RAP-loaded PHBHHx (100 μg ml-1)
and PHBHHxPEG NPs (100 μg ml-1) which contained
equal amounts of drug, respectively, for 48 h. PC3 cells
showed a dramatic inhibition of cellular proliferation
when treated with RAP-loaded NPs compared to cells
treated with free RAP at the same concentration (Figure 5).
The anti-proliferative effects persisted after 48 hours
without further addition of NPs, potentially because of
the sustained intracellular release of RAP from the NPs.
In line with the efficient cellular uptake and the fast void-
ing rate of PHBHHxPEG NPs, RAP-loaded PHBHHxPEG
NPs inhibited PC3 cell proliferation more efficiently than
RAP-loaded PHBHHx NPs.
Effects of RAP-loaded NPs on mTOR activity
p70S6K (p70 S6 ribosomal protein kinase) is a main
downstream mediator of mTOR and phosphorylationFigure 4 In vitro cytotoxicity of PHBHHx and PHBHHxPEG NPs on PC3level of p70S6K at Thr389 could be used as a probe for
mTOR activity. Different from the anti-proliferation ef-
fect on PC3, phospho-p70S6K signaling could be sig-
nificant inhibited by RAP at a very low concentration
(Figure 6), as previosly reported [11,12]. The inhibition
on mTOR activity in PC3 could also be achieved by
adjusting drug-loaded NPs dosage (10–50 ng ml-1) to
reach a final RAP concentration of either 1 or 5 nM
(Figure 7). Treatment with free RAP, RAP-loaded
PHBHHxPEG NPs and RAP-loaded PHBHHxPEG NPs
equally resulted in decreased p70S6K phosphorylation
(Thr389), without affecting total p70S6K and total mTOR
levels. This indicated that the decreased phosphorylation
level of p70S6K was only due to the inhibition of mTOR
activity but not because of the downregulation of mTOR
or p70S6K. In keeping with their anti-proliferative ef-
fects, drug-loaded PHBHHx and PHBHHxPEG NPs
demonstrated to better inhibit mTOR than free RAP.
RAP-loaded PHBHHxPEG NPs showed even stronger
inhibition effects than RAP-loaded PHBHHx NPs.
Discussion
Because poor bioavailability and limited in vivo half-life
are rather common features of many kinase inhibitors that
usually are highly hydrophobic compounds, the develop-
ment of polymer-based nanocarrier for kinase inhibitors
provided a promising strategy to improve their therapeutic
activity by releasing drugs in a sustained manner, and
consequently enhancing their bioavailability, improving
their solubility, and reducing the toxic side effects [13].
In addition, drug-carrying nanoparticles could be pas-
sively accumulated in tumor or inflammatory tissues
through the enhanced permeability and retention (EPR)
effect and thus could further increase the effectual con-
centration of hydrophobic drugs [14]. Polymeric nanopar-
ticles have been extensively studied as drug carriers [15].
Figure 5 The effect of RAP-loaded NPs on the proliferation of PC3.
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tions have been approved by the FDA for clinical appli-
cations [16]. PHAs are linear biopolyesters produced as
energy- and carbon-storage materials by many bacteria.
The medical applications of PHA have been extensively
explored in recent years for implant biomedical applica-
tions [6]. Several members of PHAs, such as PHB and
PHBHHx, have also been developed into nanoparticles
and investigated for controlled drug-release applica-
tions [8,9,17]. Our previous data indicated that they
were efficient in encapsulating hydrophobic compounds
such as the phosphoinositide-3-kinases (PI3Ks) inhibi-
tor TGX221 (Mw = 364.4). In this study, rapamycin, a
mTOR inhibitor with relative high molecular mass of
914.17, was used to investigate the entrapment and re-
lease abilities of PHA NPs for high molecular weight
kinase inhibitors. Both PHBHHx and PHBHHxPEG NPs
showed higher rapamycin entrapment efficiency (more
than 90%) and more complete drug release than that of
PLA NPs, which was consisted with the study of
TGX221-loaded PHA NPs. This indicated the advantage
of PHA-based NPs in the entrapment and sustained re-
lease of hydrophobic kinase inhibitors. The results of this
study also showed that release of rapamycin from
PHBHHxPEG NPs was faster than that from PHBHHx
NPs, which might be due to the incorporation of PEGFigure 6 Analysis of p70 S6K phosphorylation after treated
with different concentrations of RAP.fragments and the relativly low molecular weight of
PHBHHxPEG.
The incorporation of PEG could also confer more
hydrophilicity to PHBHHxPEG NPs. This might explain
the enhanced cellular uptake of PHBHHxPEG NPs, since
a hydrophobic surface is known to disturb cell inter-
action. Yang et al. reported that the surface of PHA film
demonstrated higher hydrophilicity and better cell com-
patibility after NaOH treatment [18]. This can be ex-
plained by the ability of NaOH treatment to break down
the ester bond of PHA backbone, leaving more hydroxyl
group and carboxyl group on the surface of PHA film.
Our previous study also indicated that the NaOH treat-
ment increased the surface hydrophilicity of PHBHHx
film and the neural stem cell-PHBHHx film interaction
(data not published). The hydrophilic PEG represents a
biocompatible material commonly used to enhance the
biocompatibility of an object with good cell compatibil-
ity. Therefore, the emulsification/solvent evaporation
method was used to expose PEG at the surface of
PHBHHxPEG NPs and hence to increase the hydrophil-
icity of NPs surface as well as the cell-NPs interaction.
In agreement, our results showed that cell contact was
maximal in PHBHHxPEG NPs.
PEGylation of nanocomposites was reported to be able
to resist nonspecific protein adsorption and have pro-
longed circulating half-life in vivo [19]. However, in this
study, the PHBHHxPEG NPs could not prevent the
endocytosis by RAW264.7 murine macrophage-like cells.
This might be explained by an insufficient PEG density
on the colloidal surface of PHBHHxPEG NPs. PEG-
modification of PLGA NPs is known to improve circula-
tion time, depending on the molecular weight (chain
length) and molar ratio (grafting efficiency) of PEG in-
corporation [20]. After 5 min from administration, the
remaining PLGA particles in circulation are about 5%,
Figure 7 Analysis of p70 S6K phosphorylation after treated with different concentrations of RAP-loaded NPs.
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PEG20000 modified PLGA particles, respectively. This
shows that the long PEG chain is necessary for increased
anti-clearance properties. In our study, the PHBHHxPEG
copolymer was synthesized by A. hydrophila by adding
PEG200 in the culture medium. PEG200 attacks the
carbonyl carbon of the PHBHHx chain directly and
forms the end-capped PHBHHxPEG copolymer [10].
Thus, in our experiments the incorporated PEG frag-
ment was no longer than 3–4 units in each chain.
While this was insufficient to promote the formation of
a dense, hydrophilic cloud on the surface of NPs, po-
tentially preventing macrophage-dependent opsonization,
the use of PEG200 was sufficient to optimize NPs hydro-
philicity and bioavailability.Conclusions
Overall, this study represented the potential of PHBHHxPEG
NPs as a promising kinase inhibitor delivery carrier in
anti-cancer study. Our results indicated that the entrap-
ment of rapamycin into PHBHHxPEG NPs could suffi-
ciently enhance its bioavailability and anti-proliferation
effect. Nonetheless, in vivo evaluation of circulating time
and anti-proliferation ability of the rapamycin-loaded
PHA NPs in animal models is still needed. Conversely,
the proven effectiveness in cell based assays of this
novel intracellular delivery nanocarrier opens the way
to similar formulation of other kinase inhibitors. Sincethe PHBHHxPEG NPs based drug delivery carrier could
also be internalized by other cell types such as macro-
phage, rapamycin-loaded PHBHHxPEG NPs might also
have alternative applications, for example, in the field
of immunosuppressant therapeutic tregimens.Methods
Materials
Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx)
(Mw =4 × 105) was donated by Lab of Microbiology,
Department of Biological Science and Biotechnology,
Tsinghua University (Beijing, P. R. China). PHBHHxPEG
(Mw =1.8 × 105) was produced by our group [10]. Poly
(vinyl alcohol) (PVA) (P1763), poly(DL-lactide) (PLA)
(P1691) and rhodamine B (83689) were purchased from
Sigma-Aldrich (USA). Rapamycin (S1039) was purchased
from selleckchem (USA).Preparation of drug-Loaded PHBHHx-PEG nanoparticles
The RAP-loaded NPs and rhodamine B-loaded NPs were
fabricated by a modified emulsification/solvent evapor-
ation method [8,9,21]. Briefly, 20 mg of polymers and
RAP (2 mg) or rhodamine B (1 mg) were added into
1 ml chloroform and the mixture was stirred to ensure
that all materials were dissolved. Then the polymer-
drug organic solution was slowly dropped into 20 ml of
1% PVA (w/v) under sonication. The double emulsion
was then deal with sonication using a probe sonicator
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followed by moderately stirred with a magnetic mixer
for 10 h to solidify the nano-droplets. Chloroform was
removed by volatilization at room temperature. The NPs
were collected by centrifugation at 12000 rpm for 30 min
and then washed twice with phosphate buffered saline
(PBS) solution. Three types of hydrophobic polymer
NPs (PHBHHx, PHBHHxPEG and PLA) were prepared
in this study.
Characterization of nanoparticles
The particle size distribution and polydispersity index
(PDI) were measured by a laser light scattering machine
(Zetasizer Nano ZS, Malvern, UK). The samples were
diluted into proper concentration with deionized water
and examined to determine the average particle diame-
ters and PDI. The shape of resulting NPs was observed
by JEM-2100 transmission electron microscope (JEOL
Ltd. Japan).
Entrapment efficiency and drug-loading content
measurement
The drug entrapment efficiency refers to the amount of
RAP loaded into the NPs as compared with the total
amount fed at the beginning. The RAP entrapment effi-
ciency and drug loading content (DLC) was calculated
according to the equations (1) and (2).
Entrapment efficiency %ð Þ ¼ Mt=Mið Þ  100% ð1Þ
DLC %ð Þ ¼ Mt=Mp
  100% ð2Þ
Where Mi was the mass of RAP fed initially, Mt repre-
sented for the total amount of RAP in NPs and Mp was
the mass of the resulting NPs, respectively [22]. The
amount of RAP was analyzed by high performance li-
quid chromatography (HPLC) with a SinoChrom ODS-
BP column (5 μm, 4.6 mm × 15 mm; Elite Analytical
Instruments, Dalian, P.R. China). To measure the amount
of entrapped or retained RAP in NPs, 50 microliters of
resuspended RAP-loaded NPs were dissolved in 450 μl
acetonitrile at room temperature and then stored at 4°C
for 4 hours to precipitate polymer. The supernatant was
used to perform the HPLC analysis after filtrated with
0.2 μm filter.
In vitro drug release study
In vitro release studies of RAP from PHBHHx,
PHBHHxPEG and PLA NPs were performed by the dia-
lysis bag method [22]. Briefly, 10 ml NPs suspension
was placed in a dialysis membrane bag with a molecular
weight cutoff of 8000 ~ 14000 g/mol. The bag was tied
and immersed into a 500 ml beaker with sustained run-
ning water to ensure the sufficient dissolution of RAP
in the water outside the bag. The entire system was keptat 37°C with continuous stirring. Then 50 microliters of
the NPs solution was taken out from the dialysis bag at
predetermined time intervals. The amount of retained
RAP (Cr) and the initial amount of RAP (Ci) in NPs were
determined by HPLC as mentioned in the previous sec-
tion. The released percentage was calculated according to
the equation (3).
Released percentage %ð Þ ¼ Ci‐Crð Þ=Ci 100 ð3Þ
Cell culture and proliferation assay
Human prostate cancer cell line PC3 was used to evalu-
ate the in vitro proliferation inhibition effect of RAP-
loaded NPs. PC3 cells were maintained in RPMI 1640
(Invitrogen, USA) supplemented with 10% fetal bovine
serum (Gibico) and 1% penicillin-streptomycin at 37°C
in humidified environment of 5% CO2. The medium was
replenished every other day and the cells were subcul-
tured after reached confluence.
For measurement of proliferation, cells were seeded
in triplicate at 2 × 103 cells/well in 96-well culture
plates and incubated overnight to allow cell attachment.
To evaluate the cytotoxicity of NPs, cells were treated
with empty PHBHHx NPs and PHBHHxPEG NPs with
the concentration of 100, 500 and 1000 μg/mL for 24
hours. Cells were incubated with the RAP-loaded
PHBHHx NPs, PHBHHxPEG NPs or free RAP for 24
and 48 hours to analyze the anti-proliferation effects of
RAP-loaded NPs on PC3 cell lines. Cell viability was quanti-
fied by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. The absorbance of viable cells was
measured at 570 nm using a microplate reader (Anthos
2020, Anthos Labtech Instruments, Wals., Austria). Rela-
tive cell viability was calculated with regard to that of the
cell control at 24 hour, which was set to 100% viability.
Cellular uptake of nanoparticles
Human prostate cancer cell line PC3 and a murine
macrophage cell line RAW264.7 cells were used to in-
vestigate the in vitro endocytosis of NPs. Cells were
seeded in 96-well plates at 1 × 104 cells/well and incu-
bated at 37°C with 5% CO2 in a humidified incubator
overnight to allow cell attachment, followed by treating
with rhodamine-loaded NPs (100 μg/mL) and free
rhodamine B (with equal fluorescence intensity) of for
3 h. Medium was then discarded and cells were washed
with PBS twice to remove the extracellular rhodamine B
and rhodamine B-loaded NPs. New medium was added
to each cell cultures again and PC3 and RAW264.7
cells were observed by fluorescence microscopy to eval-
uated cellular uptake of various NPs. The intracellular
fluorescence intensities were quantified by fluorescence
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mTOR inhibition assay and western blot analysis
Cells were seeded in 6-well plates at 2 × 105 cells/well
and incubated at 37°C with 5% CO2 in a humidified in-
cubator overnight to get attached and then treated with
free RAP or RAP-loaded NPs for 24 h. After washing
with cold PBS for two times, cells were lysated by adding
RIPA lysis Buffer (50 mM Tris–HCl (pH 7.4), 150 mM
NaCl, 1% NP-40), followed by incubating at 4°C for
30 min. Cell lysates were centrifuged at 10000 rpm for
5 min and supernatant was then loaded into 10% SDS–
PAGE gels. After electrophoresis, proteins were trans-
ferred onto PVDF membranes, which were then blocked
with 5% bovine serum albumin in TBST buffer for 1 h at
room temperature. PVDF membranes were incubated
overnight with an anti-phospho-p70S6 Kinase (Thr 389)
antibody (Cell Signaling Technology Inc., USA, #9205),
anti-p70S6 Kinase antibody (Cell Signaling Technology
Inc., USA, #9202), anti-mTOR antibody (Cell Signaling
Technology Inc., USA, #2972) and anti-β-actin antibody
from Beijing Biosynthesis Biotechnology (Beijing, China),
respectively, and subsequently hybridized with secondary
HRP conjugated anti-rabbit IgGs (Zhongshan Goldenbridge
Biotechnology, Beijing, China, #ZB-2301). The hybrid
signals were detected by incubating with an enhanced
chemiluminescence solution (ECL) purchased from Thermo
scientific (#LK151361). The amount of phospho-p70S6K,
total p70S6K, total mTOR and β-actin were analyzed
by Quantity One software (Bio-Rad laboratory Inc., USA)
and the relative phospho-p70S6K level was normalized
according to the amount of total p70S6K.
Statistical analysis
All results were expressed as mean ± standard deviation
of at least three independent experiments performed in
triplicates. Statistical analysis was performed using a
one-way analysis of variance (ANOVA) with Bonferroni
post-hoctest. Differences were considered to be statisti-
cally significant at a level of p < 0.05.
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